Global Technology - December 2017

Comments Off on Global Technology - December 2017
Global Technology - December 2017 LoadingADD TO FAVORITES

Researchers at the Case Western Reserve University School of Medicine have developed a computer program that finds new uses for old drugs.

The computer program, called DrugPredict, matches existing data about FDA-approved drugs to diseases, and predicts potential drug efficacy.  In a recent study published in the journal Oncogene, DrugPredict was test on epithelial ovarian cancer, which is the fifth leading cause of cancer deaths in women; it kills approximately 14,000 women annually in the United States. Available therapies are only moderately successful, with more than 70 percent of women dying within five years of diagnosis. According to the authors, part of the challenge in developing new ovarian cancer drugs lies in escalating clinical trial costs and lengthy drug development timelines. Programs like DrugPredict could “reposition” FDA-approved medications for new uses which is a far more efficient strategy.

The traditional drug discovery process takes an average of fourteen years and billions of dollars of investment for a lead anti-cancer drug to make the transition from lab to clinic, Drug re-positioning significantly shortens the long lag-phase in drug discovery and reduces the associated cost.”

In the study, DrugPredict suggested non-steroidal anti-inflammatory drugs, also known as NSAIDs, might be effective for epithelial ovarian cancer.  Based on this output, the researchers exposed patient-derived epithelial ovarian cancer cells growing in their laboratory to a specific NSAID, called indomethacin, to test the DrugPredict finding.  Indomethacin killed both drug-resistant and drug-sensitive epithelial ovarian cancer cells. Interestingly, cisplatin-resistant epithelial ovarian cancer cells were most sensitive to indomethacin.  And when the researchers added regular chemotherapy drugs to the experiments along with indomethacin, the cancer cells died even faster.

The findings may represent the first step toward a new therapy regimen for epithelial ovarian cancer.

DrugPredict works by connecting computer-generated drug profiles — including mechanisms of action, clinical efficacy, and side effects — with information about how a molecule may interact with human proteins in specific...

To continue reading, become a paid subscriber for full access.
Already a Business Briefings subscriber? Login for full access now.

Subscribe for as low as $135/year

  • Get 12 months of Business Briefings that will impact your business and your life
  • Gain access to the entire Business Briefings Research Library
  • Optional Business Briefings monthly CDs in addition to your On-Line access
  • If you do not like what you see, you can cancel anytime and receive a 100% pro-rata refund